### TUMOUR SITE

- Not specified
- Specify

### CLINICAL INTENT OF PROCEDURE

(Per information received from the clinician)

- Not specified
- Excisional/complete diagnostic biopsy
- Incisional/incomplete (partial) diagnostic biopsy
- Wide excision

### SPECIMEN LATERALITY

- Not specified
- Left
- Midline
- Right

### SPECIMEN(S) SUBMITTED

- Not specified
- Punch technique
- Shave technique (superficial)
- Saucerization/scoop/deep shave technique
- Curette
- Fusiform/elliptical/disc (full-thickness)
- Other, specify

### LYMPH NODES

- Not submitted
- Submitted, specify site(s)

### SPECIMEN ORIENTATION

(Per information received from the clinician on orientation of specimen by marking sutures, clips or other techniques)

- Not specified
- Specify, if known

### MACROSCOPIC PRIMARY LESION DESCRIPTION

(The description of the lesion includes includes such features as shape, colour, border, contour, evidence of surface crusting or ulceration and proximity to resection margins)

### MACROSCOPIC PRIMARY LESION DIMENSIONS

- Indeterminate

### MACROSCOPIC SATELLITE LESIONS

(Applicable to invasive tumours only)

- Not identified
- Present
- Indeterminate

### OTHER LESION(S)

- Not identified
- Present
- Indeterminate

### SURGICAL MARGIN/TISSUE EDGES

- Cannot be assessed
- Involved by melanoma in situ or invasive melanoma
  - Distance of melanoma in situ or invasive tumour
    - ≤1 mm
    - >1 mm
  - Specify closest location(s), if possible

### BRESLOW THICKNESS

(Measurement should be to the nearest 0.1 mm as per AJCC staging)

- Indeterminate

### ULCERATION

- Not identified
- Present
- Indeterminate

- EXTENT OF ULCERATION

- Indeterminate
<table>
<thead>
<tr>
<th><strong>MITOTIC COUNT</strong></th>
<th>/mm²</th>
<th>Indeterminate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MICROSATELLITES</strong></td>
<td>Not identified</td>
<td>Present</td>
</tr>
<tr>
<td><strong>MICROSATELLITES: MARGINS</strong></td>
<td>Cannot be assessed</td>
<td>Not involved by microsatellite</td>
</tr>
<tr>
<td><strong>CLARK LEVEL</strong></td>
<td>Confined to epidermis (Level 1)</td>
<td>Infiltrates but does not fill papillary dermis (Level 2)</td>
</tr>
<tr>
<td><strong>LYMPHOVASCULAR INVASION</strong></td>
<td>Not identified</td>
<td>Present</td>
</tr>
<tr>
<td><strong>TUMOUR-INFILTRATING LYMPHOCYTES</strong></td>
<td>Not identified</td>
<td>Brisk</td>
</tr>
<tr>
<td><strong>TUMOUR REGRESSION</strong></td>
<td>Not identified</td>
<td>Present</td>
</tr>
<tr>
<td><strong>TUMOUR REGRESSION: MARGINS</strong></td>
<td>Cannot be assessed</td>
<td>Not involved by regression</td>
</tr>
<tr>
<td><strong>NEUROTROPISM</strong></td>
<td>Not identified</td>
<td>Present</td>
</tr>
<tr>
<td><strong>DESMOPLASTIC MELANOMA COMPONENT</strong></td>
<td>Not identified</td>
<td>Present</td>
</tr>
<tr>
<td></td>
<td>Pure (&gt;90% desmoplastic melanoma)</td>
<td>Mixed desmoplastic/non-desmoplastic melanoma</td>
</tr>
<tr>
<td><strong>ASSOCIATED MELANOCYTIC LESION</strong></td>
<td>Not identified</td>
<td>Present, describe</td>
</tr>
</tbody>
</table>

**LYMPH NODES STATUS** *(Required only if lymph nodes submitted)*

### Sentinel nodes
- Number of sentinel nodes examined
- Number of positive sentinel nodes (i.e., clinically occult)
- Number cannot be determined
- Extranodal extension
- Not identified | Present | Indeterminate |
| Maximum dimension of largest metastasis in sentinel node
| Location of largest sentinel node metastases
| Subcapsular | Intraparenchymal | Both subcapsular and intraparenchymal |

### Non-sentinel lymph nodes
- Number of non-sentinel nodes examined
- Number of positive non-sentinel nodes (i.e., clinically occult)
- Number cannot be determined
- Extranodal extension
- Not identified | Present | Indeterminate |
| Maximum dimension of largest metastasis in a non-sentinel node
| Location of largest non-sentinel node metastases
| Subcapsular | Intraparenchymal | Both subcapsular and intraparenchymal |

### Clinically apparent lymph nodes
- Number of non-sentinel nodes examined
- Number of positive non-sentinel nodes
- Number cannot be determined
- Extranodal extension
- Not identified | Present | Indeterminate |
| Maximum dimension of largest metastasis in a non-sentinel node

*a Required only in the presence of positive nodes.
**PATHOLOGICAL STAGING (UICC TNM 8th edition)**

- **Primary tumour (pT)**
  - pTX: Primary tumour cannot be assessed
  - T0: No evidence of primary tumour or regressed melanomas
  - Tis: Melanoma in situ (Clark level I)
  - T1: Tumour 1 mm or less in thickness
    - T1a: less than 0.8 mm in thickness without ulceration
    - T1b: less than 0.8 mm in thickness with ulceration or 0.8 mm or more but no more than 1 mm in thickness, with or without ulceration
  - T2: Tumour more than 1 mm but not more than 2 mm in thickness
    - T2a: Without ulceration
    - T2b: With ulceration
  - T3: Tumour more than 2 mm but not more than 4 mm in thickness
    - T3a: Without ulceration
    - T3b: With ulceration
  - T4: Tumour more than 4 mm in thickness
    - T4a: Without ulceration
    - T4b: With ulceration

- **Regional lymph nodes (pN)**
  - N0: No regional lymph node metastases
  - N1: Metastasis in one regional lymph node or intralymphatic regional metastasis without nodal metastases
    - N1a: Only microscopic metastasis (clinically occult)
    - N1b: Macroscopic metastasis (clinically apparent)
    - N1c: Satellite or in-transit metastasis without regional nodal metastasis
  - N2: Metastasis in two or three regional lymph nodes or intralymphatic regional metastasis with lymph node metastases
    - N2a: Only microscopic nodal metastasis
    - N2b: Macroscopic nodal metastasis
    - N2c: Satellite or in-transit metastasis with only one regional nodal metastasis
  - N3: Metastasis in four or more regional lymph nodes, or matted metastatic regional lymph nodes, or satellite(s) or in-transit metastasis with metastasis in two or more regional lymph node(s)
    - N3a: Only microscopic nodal metastasis
    - N3b: Macroscopic nodal metastasis
    - N3c: Satellite or in-transit metastasis with two or more regional nodal metastasis

- **Ancillary Studies**

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRAF testing</td>
<td></td>
</tr>
<tr>
<td>Not performed</td>
<td></td>
</tr>
<tr>
<td>Performed</td>
<td></td>
</tr>
<tr>
<td>Record results and methodology</td>
<td></td>
</tr>
</tbody>
</table>

**MELANOMA SUBTYPE** (select all that apply)

- Low-CSD melanoma (superficial spreading melanoma)
- Lentigo maligna melanoma (high-CSD melanoma)
- Desmoplastic melanoma
- Malignant Spitz tumour (Spitz melanoma)
- Acral melanoma
- Mucosal melanomas (genital, oral, sinonasal)
- Melanoma arising in blue naevus
- Melanoma arising in giant congenital naevus
- Nodular melanoma
- Naevoid melanoma
- Melanoma, not otherwise classified
- Other, specify

**TNM Descriptors** (only if applicable) (select all that apply)

- m: multiple primary tumours
- r: recurrent
- y: post-therapy
- sn: sentinel node biopsy

**Regional lymph nodes (pN)**

- No nodes submitted or found
- NX: Regional nodes not assessed
- N0: No regional lymph node metastases
- N1: Metastasis in one regional lymph node or intralymphatic regional metastasis without nodal metastases
  - N1a: Only microscopic metastasis (clinically occult)
  - N1b: Macroscopic metastasis (clinically apparent)
  - N1c: Satellite or in-transit metastasis without regional nodal metastasis
- N2: Metastasis in two or three regional lymph nodes or intralymphatic regional metastasis with lymph node metastases
  - N2a: Only microscopic nodal metastasis
  - N2b: Macroscopic nodal metastasis
  - N2c: Satellite or in-transit metastasis with only one regional nodal metastasis
- N3: Metastasis in four or more regional lymph nodes, or matted metastatic regional lymph nodes, or satellite(s) or in-transit metastasis with metastasis in two or more regional lymph node(s)
  - N3a: Only microscopic nodal metastasis
  - N3b: Macroscopic nodal metastasis
  - N3c: Satellite or in-transit metastasis with two or more regional nodal metastasis